(Q36770191)

English

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

scientific article published on 30 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study (English)

1 reference

Europe PubMed Central

16 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

36

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

16 August 2017

Jorge Eduardo Cortes

15

object named as

Jorge Cortes

1 reference

Europe PubMed Central

16 August 2017

1

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

16 August 2017

9

object named as

Elias Jabbour

1 reference

Europe PubMed Central

16 August 2017

Gianluca Gaidano

25

object named as

Gianluca Gaidano

1 reference

Europe PubMed Central

16 August 2017

20

object named as

Johan Maertens

1 reference

Europe PubMed Central

16 August 2017

Stephen A. Strickland

7

object named as

Stephen A Strickland

1 reference

Europe PubMed Central

16 August 2017

16

object named as

Gail J Roboz

1 reference

Europe PubMed Central

16 August 2017

3

object named as

Hamid Sayar

1 reference

Europe PubMed Central

16 August 2017

Jeffrey E Lancet

4

object named as

Jeffrey E Lancet

1 reference

Europe PubMed Central

16 August 2017

6

object named as

Norbert Vey

1 reference

Europe PubMed Central

16 August 2017

Gary J Schiller

8

object named as

Gary J Schiller

1 reference

Europe PubMed Central

16 August 2017

10

object named as

Harry P Erba

1 reference

Europe PubMed Central

16 August 2017

11

object named as

Arnaud Pigneux

1 reference

Europe PubMed Central

16 August 2017

Heinz-August Horst

12

object named as

Heinz-August Horst

1 reference

Europe PubMed Central

16 August 2017

Christian Récher

13

object named as

Christian Recher

1 reference

Europe PubMed Central

16 August 2017

Virginia M Klimek

14

object named as

Virginia M Klimek

1 reference

Europe PubMed Central

16 August 2017

Olatoyosi Odenike

17

object named as

Olatoyosi Odenike

1 reference

Europe PubMed Central

16 August 2017

Bayard L Powell

24

object named as

Bayard L Powell

1 reference

Europe PubMed Central

16 August 2017

Angelo Michele Carella

26

object named as

Angelo-Michele Carella

1 reference

Europe PubMed Central

16 August 2017

33

object named as

Gary Acton

1 reference

Europe PubMed Central

16 August 2017

23

object named as

Lloyd Damon

1 reference

Europe PubMed Central

16 August 2017

author name string

Ellen K Ritchie

2

1 reference

Europe PubMed Central

16 August 2017

Michael D Craig

5

1 reference

Europe PubMed Central

16 August 2017

Xavier Thomas

18

1 reference

Europe PubMed Central

16 August 2017

Violaine Havelange

19

1 reference

Europe PubMed Central

16 August 2017

Hans-Günter Derigs

21

1 reference

Europe PubMed Central

16 August 2017

Michael Heuser

22

1 reference

Europe PubMed Central

16 August 2017

Andrew Wei

27

1 reference

Europe PubMed Central

16 August 2017

Donna Hogge

28

1 reference

Europe PubMed Central

16 August 2017

Adam R Craig

29

1 reference

Europe PubMed Central

16 August 2017

Judith A Fox

30

1 reference

Europe PubMed Central

16 August 2017

Renee Ward

31

1 reference

Europe PubMed Central

16 August 2017

Jennifer A Smith

32

1 reference

Europe PubMed Central

16 August 2017

Cyrus Mehta

34

1 reference

Europe PubMed Central

16 August 2017

Robert K Stuart

35

1 reference

Europe PubMed Central

16 August 2017

publication date

30 July 2015

1 reference

Europe PubMed Central

16 August 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

Lancet Oncology Commission

1 reference

Europe PubMed Central

16 August 2017

16

1 reference

Europe PubMed Central

16 August 2017

9

1 reference

Europe PubMed Central

16 August 2017

1025-1036

1 reference

Europe PubMed Central

16 August 2017

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Endpoints for assessing drug activity in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

29 September 2017

Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Adaptive sample size calculations in group sequential trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Modification of sample size in group sequential clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822512

5 September 2018

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myeloid leukaemia in the elderly: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of cytokines in the treatment of acute leukemias: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900201-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00201-6

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36770191&oldid=1858464681"